Abstract: A non-acidified fermented dairy product and a preparation method thereof are provided, relating to the technical field of fermented dairy products processing. The preparation method of the non-acidified fermented dairy product includes: inoculating a fermentation inoculum into cow milk, and performing a two-stage fermentation to obtain the non-acidified fermented milk; wherein the two-stage fermentation comprises a first-stage fermentation and a second-stage fermentation; a rotation speed of the first-stage fermentation is 180-250 revolutions per minute, and a duration is 10-20 hours; a rotation speed of the second-stage fermentation is 100-160 revolutions per minute, and a duration is 8-16 hours.

Abstract: A method for lowering cholesterol and lipid levels using the Antrodia cinnamomea water-insoluble dietary fiber prepared as herein. After ethanol and water extraction, Antrodia cinnamomea wastes are dried and superfine-comminuted to obtain Antrodia cinnamomea waste powder. The waste powder treated with NaOH solution containing NaBH4 is extracted it twice to obtain two extracts. The two extracts are combined and an appropriate amount of glacial acetic acid are added for neutralization. The extracts are centrifugalized and precipitate is collected. After washing the precipitate with ultrapure water, the precipitate is dissolved with LiCl-DMSO. The precipitate that is insoluble in the LiCl-DMSO solution is dialyzed and freeze-dried to obtain the water-insoluble dietary fiber component ACA-IDK of Antrodia cinnamomea. The LiCl-DMSO solution is subjected to ethanol/DMSO fractional precipitation, and then the precipitate is collected and dialyzed.

Abstract: A preparation method of Antrodia cinnamomea water-insoluble dietary fiber. After ethanol and water extraction, Antrodia cinnamomea wastes are dried and superfine-comminuted to obtain Antrodia cinnamomea waste powder. The waste powder treated with NaOH solution containing NaBH4 is extracted it twice to obtain two extracts. The two extracts are combined and an appropriate amount of glacial acetic acid are added for neutralization. The extracts are centrifugalized and precipitate is collected. After washing the precipitate with ultrapure water, the precipitate is dissolved with LiCl-DMSO. The precipitate that is insoluble in the LiCl-DMSO solution is dialyzed and freeze-dried to obtain the water-insoluble dietary fiber component ACA-IDK of Antrodia cinnamomea. The LiCl-DMSO solution is subjected to ethanol/DMSO fractional precipitation, and then the precipitate is collected and dialyzed. The water-insoluble dietary fiber component ACA-DK of Antrodia cinnamomea is obtained after freeze-drying.

Abstract: A Lactobacillus plantarum strain AR113 with protection effect on apoplexy. The Lactobacillus plantarum strain AR113 deposited in China General Microbiological Culture Collection Center (CGMCC) under CGMCC Accession No. 13909 on Mar. 22, 2017. The Lactobacillus plantarum AR113 strain can increase the antioxidant enzyme activity of brain tissue, reduce the level of oxidation products, activate the Nrf-ARE signal pathway, and regulate the relative expression of antioxidant factors Nrf2, NQO-1, and HO-1. Additionally, it can down-regulate the mRNA expression of pro-apoptotic factors Cyt-C, Caspase-3 and Bax, and up-regulate the relative expression of anti-apoptotic factor Bcl-2, thereby improving brain cell damage caused by cerebral ischemia and reperfusion.

Abstract: A preparation method of Antrodia cinnamomea water-insoluble dietary fiber. After ethanol and water extraction, Antrodia cinnamomea wastes are dried and superfine-comminuted to obtain Antrodia cinnamomea waste powder. The waste powder treated with NaOH solution containing NaBH4 is extracted it twice to obtain two extracts. The two extracts are combined and an appropriate amount of glacial acetic acid are added for neutralization. The extracts are centrifugalized and precipitate is collected. After washing the precipitate with ultrapure water, the precipitate is dissolved with LiCl-DMSO. The precipitate that is insoluble in the LiCl-DMSO solution is dialyzed and freeze-dried to obtain the water-insoluble dietary fiber component ACA-IDK of Antrodia cinnamomea. The LiCl-DMSO solution is subjected to ethanol/DMSO fractional precipitation, and then the precipitate is collected and dialyzed. The water-insoluble dietary fiber component ACA-DK of Antrodia cinnamomea is obtained after freeze-drying.

Abstract: The present invention relates to a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof. The yield of the polyketide heterologously synthesized by E. coli is significantly increased by attenuating the expression of seventy-two genes, such as sucC and talB, in a host strain, wherein the highest yield increase rate can reach 60% or more. Currently, erythromycin is the most clear model compound in the study on the biosynthesis of polyketids. The production strain of the present invention enables massive accumulation of 6-deoxyerythronolide (6-dEB), an erythromycin precursor, in the fermentation process, laying the foundation for the industrial production of the heterologous synthesis of erythromycin by E. coli.

Abstract: The present invention relates to a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof. The yield of the polyketide heterologously synthesized by E. coli is significantly increased by attenuating the expression of seventy-two genes, such as sucC and talB, in a host strain, wherein the highest yield increase rate can reach 60% or more. Currently, erythromycin is the most clear model compound in the study on the biosynthesis of polyketids. The production strain of the present invention enables massive accumulation of 6-deoxyerythronolide (6-dEB), an erythromycin precursor, in the fermentation process, laying the foundation for the industrial production of the heterologous synthesis of erythromycin by E. coli.

Abstract: The present invention provides a method for producing stevioside compounds by microorganism, comprising carrying out heterologous biosynthesis of stevioside compounds from geranyl geranyl pyrophosphate synthase (GGPPS), Copalyl pyrophosphate synthase (CDPS), Kaurene synthase (KS), dual-function kaurene synthase (CPS/KS), kaurene oxidase (KO), a cytochrome P450 redox protein (CPR), kaurenoic acid-13[alpha]-hydroxylase, UGT85C2 glycosyltransferase and UGTB1/IBGT glycosyltransferase (optionally comprising UGT74G1 glycosyltransferase and/or UGT76G1 glycosyltransferase).

Abstract: A method for acquiring a physical address of a virtual machine includes acquiring, by a first switching endpoint, an address list of N switching endpoints from a centralized controller after receiving an address acquisition request sent by a first virtual machine, where the N switching endpoints include a second switching endpoint, sending, in a unicast manner according to the address list, the request to the N switching endpoints that include the second switching endpoint, and after receiving a second response sent by the second switching endpoint, sending the second response to the first virtual machine. The method may avoid the limitation on the quantity of created switching endpoints caused by the insufficient quantity of multicast groups of the switch in order to increase the quantity of created switching endpoints.

Abstract: A method for acquiring a physical address of a virtual machine includes acquiring, by a first switching endpoint, an address list of N switching endpoints from a centralized controller after receiving an address acquisition request sent by a first virtual machine, where the N switching endpoints include a second switching endpoint, sending, in a unicast manner according to the address list, the request to the N switching endpoints that include the second switching endpoint, and after receiving a second response sent by the second switching endpoint, sending the second response to the first virtual machine. The method may avoid the limitation on the quantity of created switching endpoints caused by the insufficient quantity of multicast groups of the switch in order to increase the quantity of created switching endpoints.

Abstract: A communication method includes a transmit-end tunnel end points (VTEP) may intercept a broadcast packet that does not have a destination address and that is sent by a transmit-end virtual machine, acquire an Internet Protocol (IP) address list of a receive-end VTEP that belongs to same virtual extensible local area network (VXLAN) as the transmit-end VTEP, encapsulate the broadcast packet into a unicast packet according to an IP address of the receive-end VTEP, and send, in a form of the unicast packet, the original packet to another receive-end VTEP on the same VXLAN, where avoiding using a multicast manner to perform communication between VTEPs on the VXLAN such that construction of the VXLAN no longer depends on a multicast group quantity or capability of a tunnel end point, which extends application of the VXLAN.

Abstract: A packet forwarding method and a VXLAN gateway. A VXLAN packet is received. The VXLAN packet includes a communication packet that is sent from a first VM to a second VM; a second VNI of a subnet in which a next-hop device of the communication packet is located is determined according to a first VNI of the VXLAN packet and an IP address of the second VM of the VXLAN packet; the communication packet is encapsulated according to the second VNI; and then an encapsulated VXLAN packet is forwarded to the next-hop device through a tunnel corresponding to the second VNI, to avoid that the VXLAN gateway can implement forwarding of the VXLAN packet only after the VXLAN gateway modifies the communication packet in the payload of the VXLAN packet, and improve efficiency of forwarding the VXLAN packet.

Abstract: The present invention provides a method for producing stevioside compounds by microorganism, comprising carrying out heterologous biosynthesis of stevioside compounds from geranyl geranyl pyrophosphate synthase (GGPPS), Copalyl pyrophosphate synthase (CDPS), Kaurene synthase (KS), dual-function kaurene synthase (CPS/KS), kaurene oxidase (KO), a cytochrome P450 redox protein (CPR), kaurenoic acid-13[alpha]-hydroxylase, UGT85C2 glycosyltransferase and UGTB1/IBGT glycosyltransferase (optionally comprising UGT74G1 glycosyltransferase and/or UGT76G1 glycosyltransferase).